Fundraising Fox
Azadyne
2 known investors
Find your way into Azadyne
Sign up to see every warm intro you have to Azadyne
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Azadyne team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Azadyne is a UK biotech company and spin-out from Trinity College Dublin developing therapeutics based on tRNA modification and epigenetic regulation of cellular protein synthesis. Its work targets the treatment of disease through this novel mechanism.
Founders & leadership
Board
JR
Jason Rutt
Investors · 2
Related companies · 1
Companies working in the same space as Azadyne.
Companies House · registry record
View on Companies House ↗- Registered name
- AZADYNE LTD
- Company number
- 11740078
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 24 Dec 2018
- Registered office
- 101 New Cavendish Street, 1st Floor South, London, W1W 6XH
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- FREYAGEN LIMITED (2018–2019)
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 23 Dec 2025 · next due 6 Jan 2027
Current officers · 4
- Stephen Joseph Connon — director, appointed 21 Feb 2019
- Jason Edward Rutt — director, appointed 24 Dec 2018
- Jonathan Stuart Synett — director, appointed 13 May 2019
- Paul Michael Tselentis — director, appointed 10 Nov 2022
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Azadyne do?
- Azadyne is a UK biotech company and spin-out from Trinity College Dublin developing therapeutics based on tRNA modification and epigenetic regulation of cellular protein synthesis. Its work targets the treatment of disease through this novel mechanism.
- Who founded Azadyne?
- Azadyne was founded by Vincent Kelly, Stephen Connon.
- Who are Azadyne's investors?
- Azadyne's investors include 24 Haymarket, NCL Technology Ventures Ltd..